GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Equity-to-Asset

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Equity-to-Asset : 0.89 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bellevue Life Sciences Acquisition's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $32.52 Mil. Bellevue Life Sciences Acquisition's Total Assets for the quarter that ended in Dec. 2023 was $36.63 Mil.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's Equity-to-Asset or its related term are showing as below:

BLAC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.03   Med: 0   Max: 0.89
Current: 0.89

During the past 4 years, the highest Equity to Asset Ratio of Bellevue Life Sciences Acquisition was 0.89. The lowest was -0.03. And the median was 0.00.

BLAC's Equity-to-Asset is ranked better than
64.99% of 617 companies
in the Diversified Financial Services industry
Industry Median: 0.82 vs BLAC: 0.89

Bellevue Life Sciences Acquisition Equity-to-Asset Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Equity-to-Asset Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
- - -0.03 0.89

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.03 0.97 0.96 0.96 0.89

Competitive Comparison of Bellevue Life Sciences Acquisition's Equity-to-Asset

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellevue Life Sciences Acquisition's Equity-to-Asset Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Equity-to-Asset falls into.


Bellevue Life Sciences Acquisition Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bellevue Life Sciences Acquisition's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=32.519/36.628
=

Bellevue Life Sciences Acquisition's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=32.519/36.628
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bellevue Life Sciences Acquisition  (NAS:BLAC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Bellevue Life Sciences Acquisition Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Equity-to-Asset
Comparable Companies
ADEX NBST RWOD PMGM QDRO ONYX BOWN MSSA TBMC VII PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004